Say Again? Startups Aim To Develop Drug Options For Hearing Loss Market
This article was originally published in The Pink Sheet Daily
Executive Summary
A host of venture-backed drug makers are racing to pass the proof-of-concept hurdle and attract big-pharma deals, which so far have been sparse.
You may also be interested in...
The Sound Of Opportunity: Novartis Inks Deal With GenVec For Hearing Loss R&D
GenVec's gene-based program targets a hearing loss world ruled by devices.
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
One Trial Plus Supportive Evidence Is Enough For Hospital-, Ventilator-Acquired Pneumonia Indication, Panel Says
Anti-Infective Drugs Advisory Committee members viewed one-trial as practical means of gaining efficacy data.